酶联免疫法测定甘精胰岛素中单链前体残留研究

doi:10.19803/j.1672-8629.20230404

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (3): 290-294.
DOI: 10.19803/j.1672-8629.20230404

• 药品质量控制及评价专栏 • 上一篇下一篇

酶联免疫法测定甘精胰岛素中单链前体残留研究

张孝明, 吕萍, 胡馨月, 丁晓丽, 李晶^#, 梁成罡^*

中国食品药品检定研究院化学药品检定所,国家卫生健康委员会生物技术产品检定方法及其标准化重点实验室,北京 102629

收稿日期:2023-06-28 出版日期:2024-03-15 发布日期:2024-03-18
通讯作者: ^*梁成罡,男,博士,研究员,激素及生物技术药物质量控制。E-mail: liangchenggang@nifdc.org.cn;^#为共同通信作者。
作者简介:张孝明,女,博士,助理研究员,生物技术药物质量控制。
基金资助:
国家重点研发计划（2021YFF0600804）

Detection of single-chain precursor residues in insulin glargine by ELISA

ZHANG Xiaoming, LYU Ping, HU Xinyue, DING Xiaoli, LI Jing^#, LIANG Chenggang^*

Institute for Chemical Drug Control, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing 102629, China

Received:2023-06-28 Online:2024-03-15 Published:2024-03-18

摘要/Abstract

摘要： 目的建立酶联免疫法检测甘精胰岛素中单链前体残留,为甘精胰岛素药物质量控制和安全性评价提供新方法。方法采用双抗夹心酶联免疫法,以甘精胰岛素原为标准品,建立单链前体残留检测方法,验证方法的重复性、准确度、范围和精密度,并应用该方法检测9批甘精胰岛素原料药。结果在0.156~10.00 ng·mL^-1浓度范围内,对甘精胰岛素原标准品进行四参数曲线拟合,曲线相关系数 R²大于0.99,方法准确度较高、重复性良好。重复检测3批甘精胰岛素原料药,平均加标回收率在104%~113%范围内,RSD%小于10%,方法精密度良好。9批样品中单链前体残留量均小于1 ng·mg^-1。结论建立的酶联免疫法可用于甘精胰岛素及其他重组人胰岛素类似物中单链前体残留量的质量控制和安全性评价。

关键词: 酶联免疫法, 甘精胰岛素, 单链前体, C肽, 质量控制, 方法学验证, 安全性, 回收率

Abstract: Objective To establish an enzyme-linked immunoassay for the detection of single-chain precursor residues in insulin glargine so as to recommend a new method for quality control and safety evaluation of insulin glargine. Methods An enzyme-linked immunoassay based on double antibody sandwich was established by using proinsulin glargine as the standard. The repeatability, accuracy, scope and precision of the method were verified, and nine batches of insulin glargine drug substances were tested using this method. Results Four-parameter curve fitting was performed using the proinsulin glargine standard at concentrations ranging from 0.156 to 10.00 ng·mL^-1, and the correlation coefficient of the curve exceeded 0.99. This method was highly accurate and repeatable. Three batches of insulin glargine drug substances were repeatedly detected. The average recovery ranged from 104% to 113%, and the RSD% was less than 10%, suggesting the good precision of this method. The single-chain precursor residues in all the nine batches were less than 1 ng·mg^-1. Conclusion The enzyme-linked immunoassay established in this study can be used for quality control and safety evaluation of single-chain precursor residues in insulin glargine and other recombinant human insulin analogues.

Key words: enzyme linked immunosorbent assay(ELISA), insulin glargine, single-chain precursor, C peptide, quality control, method validation, safety, recovery rate

中图分类号:

R917

张孝明, 吕萍, 胡馨月, 丁晓丽, 李晶, 梁成罡. 酶联免疫法测定甘精胰岛素中单链前体残留研究[J]. 中国药物警戒, 2024, 21(3): 290-294.

ZHANG Xiaoming, LYU Ping, HU Xinyue, DING Xiaoli, LI Jing, LIANG Chenggang. Detection of single-chain precursor residues in insulin glargine by ELISA[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 290-294.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230404

https://www.zgywjj.com/CN/Y2024/V21/I3/290

参考文献

[1] SEBASTIAN SA, CO EL, MEHENDALE M, et al.Insulin analogs in the treatment of type II diabetes and future perspectives[J]. Dis Mon, 2023, 69(3): 1-11.
[2] KABRA UD, JASTROCH M.Mitochondrial dynamics and insulin secretion[J]. Int J Mol Sci, 2023, 24(18): 2-19.
[3] VARGAS-URICOECHEA H.Current state and principles of basal insulin therapy in type 2 diabetes[J]. J Clin Med Res, 2022, 14(1): 8-21.
[4] LE TKC, DAO XD, NGUYEN DV, et al.Insulin signaling and its application[J]. Front Endocrinol[J], 2023, 8(14): 1-9.
[5] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China, Volume III(中华人民共和国药典三部)[M]. Beijing: China Medical Science Press, 2020: 466-472.
[6] USP. Usp2022-NF[S/OL].(2022-12-01). https://online.uspnf.com/uspnf/document/1_GUID-1FB2BBF9-9095-4966-BB9B-4B549843ED43_5_en-US?source=Activity.
[7] EDQM. European Pharmacopoeia 11.4[S]. Strasbourg Cedex: European Directorate for the Quality of Medicines & HealthCare, 2022: 3088-3090.
[8] HAZRA P, SREENIVAS S, VENKATESAN K, et al.A novel peptide design aids in the expression and its simplified process of manufacturing of Insulin Glargine in Pichia pastoris[J]. Appl Microbiol Biotechnol, 2021, 105(8): 3061-3074.
[9] LENG C, LI Q, WU F, et al.Detection of the single-chain precursor in the production and purification process of recombinant human insulin[J]. Monoclon Antib Immunodiagn Immunother, 2013, 32(4): 255-261.
[10] DING XL, G YP, ZHANG H, et al. Determination of insulin precursor in recombinant human insulin by RP-HPLC[J]. Chinese Journal of New Drugs(中国新药杂志), 2015, 24(15): 1707-1710.
[11] SIEW YY, ZHANG W.Downstream processing of recombinant human insulin and its analogues production from E. coli inclusion bodies[J]. Bioresour Bioprocess, 2021, 8(1): 65.
[12] XU KZ, LYU P, DING XL, et al.Detection of tetracycline residue in insulin preparation of lispro[J]. Chinese Journal of New Drugs(中国新药杂志), 2022, 31(19): 1883-1887.
[13] CHANCE RE, FRANK BH.Research, development, production, and safety of biosynthetic human insulin[J]. Diabetes Care, 1993, 16(Suppl 3): 133-142.
[14] COWLEY DJ, MACKIN RB.Expression, purification and characterization of recombinant human proinsulin[J]. FEBS Lett, 1997, 402(2-3): 124-130.
[15] BAESHEN NA, BAESHEN MN, SHEIKH A, et al.Cell factories for insulin production[J]. Microb Cell Fact, 2014, 13(1): 141-150.
[16] REDWAN M, MATAR SM, EL-AZIZ GA, et al.Synthesis of the human insulin gene: protein expression, scaling up and bioactivity[J]. Prep Biochem Biotechnol, 2008, 38(1): 24-39.
[17] KJELDSEN T.Yeast secretory expression of insulin precursors[J]. Appl Microbiol Biotechnol, 2000, 54(3): 277-286.
[18] WEISS MA.Diabetes mellitus due to the toxic misfolding of proinsulin variants[J]. FEBS Lett, 2013, 587(13): 1942-1950.
[19] PFÜTZNER A, KANN PH, PFüTZNER AH, et al. Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance[J]. Clin Lab, 2004, 50(9-10): 567-573.
[20] GALLOWAY JA, HOOPER SA, SPRADLIN CT, et al.Biosynthetic human proinsulin: review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience[J]. Diabetes Care, 1992, 15(5): 666-692.
[21] YUDKIN JS.Circulating proinsulin-like molecules[J]. J Diabetes Complications, 1993, 7(2): 113-123.
[22] LIANG CG, LI J, ZHANG H, et al.Considerations on research of national standards for recombinant hormones[J]. Chin J Pharm Anal(药物分析杂志), 2022, 42(1): 3-12.

酶联免疫法测定甘精胰岛素中单链前体残留研究

Detection of single-chain precursor residues in insulin glargine by ELISA

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	杨波, 王梦娇, 胡丽丽, 王来成, 李倩, 孔飞飞, 吕冬梅, 沈佳妮. 385例PD-1抗肿瘤治疗的安全性研究及风险因素分析[J]. 中国药物警戒, 2024, 21(4): 447-450.
[2]	顾晓彤, 孙雪林, 郑丽. 治疗念珠菌血症与侵袭性念珠菌感染新药rezafungin药理作用及临床评价研究进展[J]. 中国药物警戒, 2024, 21(4): 469-472.
[3]	刘毅, 覃玲, 郭贤辉, 陈华, 裴宇盛. 热重和差示扫描量热分析技术在药物分析中的应用进展[J]. 中国药物警戒, 2024, 21(3): 283-289.
[4]	王丹丹, 王莹, 姚令文, 刘芫汐, 金红宇, 马双成. 顶空-气相色谱法测定到手香提取物11种溶剂残留量[J]. 中国药物警戒, 2024, 21(3): 295-299.
[5]	刘琦, 张玉凤, 罗皓, 李歆. 106例安罗替尼临床应用的合理性与安全性分析[J]. 中国药物警戒, 2024, 21(3): 329-334.
[6]	王常顺, 王晓蕾, 段吉平, 袁浩, 刘永利, 赵丁. 硫磺熏蒸对白芷质量的影响及产地替代加工方式探讨[J]. 中国药物警戒, 2024, 21(3): 355-360.
[7]	贾茵茵, 张财树, 周颖, 刘丽, 耿颖, 魏宁漪, 钮思静, 陈华, 许卉. 吸入制剂微细粒子空气动力学粒径分布评价方法研究[J]. 中国药物警戒, 2024, 21(2): 141-146.
[8]	柏兆方, 湛小燕, 姚清, 陈思敏, 赵旭, 肖小河. 中药安全性评价理论创新与技术突破：病证毒理学[J]. 中国药物警戒, 2024, 21(1): 6-14.
[9]	方志娥, 李承贤, 柏兆方, 赵旭, 王伽伯, 肖小河. 马兜铃酸致肝癌的客观性研究与思考[J]. 中国药物警戒, 2024, 21(1): 20-24.
[10]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[11]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	刘倩, 胡晶, 李博, 杨小静. 荆花胃康胶丸联合四联疗法治疗幽门螺旋杆菌相关性胃炎的系统评价及Meta分析[J]. 中国药物警戒, 2023, 20(9): 1039-1045.
[15]	于洪礼, 于冬梅, 肖爱丽, 朱兰, 宋海波. 清开灵口服制剂安全性风险分析[J]. 中国药物警戒, 2023, 20(9): 1046-1048.